EV71-CA16 bivalent vaccine

The EV71-CA16 bivalent vaccine is an inactivated bivalent vaccine candidate developed by AIM Vaccine (specifically through its subsidiary AIM Kanghuai Biopharmaceutical) for the prevention of hand-foot-and-mouth disease (HFMD). It is designed to simultaneously target the two most common pathogens responsible for HFMD: enterovirus 71 (EV71) and coxsackievirus A16 (CA16). Cultured in human diploid cells, the vaccine aims to provide broad protective immunity against both viral strains. It is currently in Phase I clinical development in China.

Other names

Enterovirus Type71 - Coxsackievirus Type A16 bivalent vaccineEV71-CA16 bivalent HFMD vaccineEV-71-CA16 bivalent HFMD vaccineEV 71-CA16 bivalent HFMD vaccineEV71-CA16 bivalent hand-foot-and-mouth disease vaccineEV-71-CA16 bivalent hand-foot-and-mouth disease vaccineEV 71-CA16 bivalent hand-foot-and-mouth disease vaccineEV71-CA16 bivalent inactivated hand, foot, and mouth disease vaccineEV71-CA16二价手足口病灭活疫苗（人二倍体细胞）EV71-CA16二价手足口病疫苗